MedicaMetrix Appoints Jeff Muzzy as Chief Technology Officer

Muzzy brings distinctive technology and business leadership experience to MedicaMetrix

BOSTON, MASSACHUSETTS (June 15, 2020) (GLOBE NEWSWIRE) — MedicaMetrix, LLC, a leader in developing and marketing innovative medical devices and healthcare solutions, today announced the appointment of Jeff Muzzy as Chief Technology Officer effective June 15, 2020.

Jeff Muzzy is a talented leader who has architected, designed, launched and operated new technology-based products and services on a global scale. Jeff has worked thirty-five years in the tech industry spanning multibillion-dollar companies to early-stage startups.

Muzzy was a leader on teams that designed and released Microsoft Windows (1.0 – XP, Win 10), Microsoft Word, Excel, and Exchange. Muzzy was the System Architect for the MSN Backend Services and Application Architecture. These systems, such as MSN Weather, Sports and News, support multiple billions of requests per day. Muzzy has eleven years working with IOT (Internet of Things) in the automotive sector designing connected car distribution. Jeff has worked as a partner for Ford (Sync), GM (OnStar), Nissan- Renault (Connect and Alliance), Chrysler-Fiat (UConnect). Muzzy has also created several hardware and software platforms used by millions of users daily.

Muzzy serves on the board of several technology companies, including an AI (Artificial Intelligence) company that is developing computer vision and alerts for automobiles, and a technology company for process automation of sports equipment.

“Jeff is one of the true visionary architects behind the world’s global IT infrastructure,” stated Robert Rudelius, President and CEO of MedicaMetrix. “Jeff’s unique background, bringing IT expertise and business impact across multiple industries, means MedicaMetrix technology strategy and operations will be in very good hands. We are delighted to welcome Jeff to our executive team.”

About MedicaMetrix
MedicaMetrix develops innovative technologies and device solutions that transform the healthcare status quo, leading to better medical outcomes, streamlined care and enhanced patient experience.

We are leading the development of a new paradigm that transforms the diagnosis, treatment, and management of prostate health by filling the gap between PSA testing and imaging / biopsies. The ProstaMetrix system is a minimally invasive medical device designed to accurately measure the volume of the prostate gland early in the diagnostic process. ProstaMetrix helps physicians assess a patient’s prostate status to better plan and monitor diagnostic procedures, treatments, drug therapies, and guide recommendations for active surveillance versus prostate biopsies.

MedicaMetrix is planning to acquire and develop other new medical devices with the goal to bring them to market rapidly by leveraging our planned production facilities in the U.S. and India.

Cautionary Statements Concerning Forward-Looking Statements
This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events, or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements related to the expected impact of COVID-19 on our business, statements regarding our growth, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our assessment of our internal controls over financial reporting, our visibility at and sponsorship of conferences and educational events. The forwardlooking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this press release should be evaluated together with the many uncertainties that affect our business and our market, as well as other risks and cautionary statements set forth in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances, or otherwise.

Connect with us

Stay up-to-date with MedicaMetrix news and products.